DGAT-1 inhibitorDiacylglycerol acyltransferase (DGAT1) inhibitor CAS# 701232-20-4 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
- Ellagic acid
Catalog No.:BCN5533
CAS No.:476-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 701232-20-4 | SDF | Download SDF |
PubChem ID | 9865421 | Appearance | Powder |
Formula | C22H26N4O3 | M.Wt | 394.5 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | DGAT-1 inhibitor | ||
Solubility | DMSO : ≥ 50 mg/mL (126.75 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid | ||
SMILES | CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)C | ||
Standard InChIKey | FUIYMYNYUHVDPT-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H26N4O3/c1-22(2)19(26-18-20(23)24-12-25-21(18)29-22)16-9-7-15(8-10-16)14-5-3-13(4-6-14)11-17(27)28/h7-10,12-14H,3-6,11H2,1-2H3,(H,27,28)(H2,23,24,25) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.
IC50 value:
Target: DGAT1
T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice. References: |
DGAT-1 inhibitor Dilution Calculator
DGAT-1 inhibitor Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5349 mL | 12.6743 mL | 25.3485 mL | 50.6971 mL | 63.3714 mL |
5 mM | 0.507 mL | 2.5349 mL | 5.0697 mL | 10.1394 mL | 12.6743 mL |
10 mM | 0.2535 mL | 1.2674 mL | 2.5349 mL | 5.0697 mL | 6.3371 mL |
50 mM | 0.0507 mL | 0.2535 mL | 0.507 mL | 1.0139 mL | 1.2674 mL |
100 mM | 0.0253 mL | 0.1267 mL | 0.2535 mL | 0.507 mL | 0.6337 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
diacylglycerol acyltransferase (DGAT1) inhibitor
- BMS-626529
Catalog No.:BCC1427
CAS No.:701213-36-7
- 5-Pentacosylresorcinol
Catalog No.:BCN4263
CAS No.:70110-61-1
- 5-Tricosyl-1,3-benzenediol
Catalog No.:BCN4262
CAS No.:70110-60-0
- 5-Heneicosylresorcinol
Catalog No.:BCN7630
CAS No.:70110-59-7
- TCN 237 dihydrochloride
Catalog No.:BCC6111
CAS No.:700878-19-9
- LY2157299
Catalog No.:BCC3709
CAS No.:700874-72-2
- LY2109761
Catalog No.:BCC3806
CAS No.:700874-71-1
- Acronycine
Catalog No.:BCC8114
CAS No.:7008-42-6
- 4,10-Aromadendranediol
Catalog No.:BCN4261
CAS No.:70051-38-6
- LPYFD-NH2
Catalog No.:BCC6113
CAS No.:700361-48-4
- Rivularin
Catalog No.:BCN3189
CAS No.:70028-59-0
- Terazosin HCl
Catalog No.:BCC4354
CAS No.:70024-40-7
- Talopram hydrochloride
Catalog No.:BCC7579
CAS No.:7013-41-4
- Liquiritic acid
Catalog No.:BCN8332
CAS No.:10379-72-3
- Isotetrandrine N-2'-oxide
Catalog No.:BCN4264
CAS No.:70191-83-2
- Papain Inhibitor
Catalog No.:BCC1024
CAS No.:70195-20-9
- Taranabant
Catalog No.:BCC1985
CAS No.:701977-09-5
- 3-Aminoadamantan-1-ol
Catalog No.:BCC8618
CAS No.:702-82-9
- 8alpha-Hydroxy-alpha-gurjunene
Catalog No.:BCN4265
CAS No.:70206-70-1
- (±)-Lauroylcarnitine chloride
Catalog No.:BCC6690
CAS No.:7023-03-2
- Physalin H
Catalog No.:BCN7917
CAS No.:70241-09-7
- BX-912
Catalog No.:BCC1250
CAS No.:702674-56-4
- BX795
Catalog No.:BCC3635
CAS No.:702675-74-9
- CP 775146
Catalog No.:BCC7881
CAS No.:702680-17-9
JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice.[Pubmed:26354408]
J Pharmacol Sci. 2015 Sep;129(1):51-8.
Type 2 diabetes mellitus (T2DM) arises primarily due to lifestyle factors and genetics. A number of lifestyle factors are known to be important in the development of T2DM, including obesity. JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase 1 inhibitor, reduced body weight depending on dietary fat in diet-induced obesity (DIO) rats in our previous study. Here, the effect of JTT-553 on glucose metabolism was evaluated using body weight reduction in T2DM mice. JTT-553 was repeatedly administered to DIO and KK-A(y) mice. JTT-553 reduced body weight gain and fat weight in both mouse models. In DIO mice, JTT-553 decreased insulin, non-esterified fatty acid (NEFA), total cholesterol (TC), and liver triglyceride (TG) plasma concentrations in non-fasting conditions. JTT-553 also improved insulin-dependent glucose uptake in adipose tissues and glucose intolerance in DIO mice. In KK-A(y) mice, JTT-553 decreased glucose, NEFA, TC and liver TG plasma concentrations in non-fasting conditions. JTT-553 also decreased glucose, insulin, and TC plasma concentrations in fasting conditions. In addition, JTT-553 decreased TNF-alpha mRNA levels and increased GLUT4 mRNA levels in adipose tissues in KK-A(y) mice. These results suggest that JTT-553 improves insulin resistance in adipose tissues and systemic glucose metabolism through reductions in body weight.
Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.[Pubmed:25740267]
Int J Clin Pharmacol Ther. 2015 May;53(5):345-55.
OBJECTIVE: An in vitro drugdrug interaction (DDI) study was performed to assess the potential for pradigastat to inhibit breast cancer resistance protein (BCRP), organic anion-transporting polypeptide (OATP), and organic anion transporter 3 (OAT3) transport activities. To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted. METHODS: The study used cell lines that stably expressed or over-expressed the respective transporters. The clinical study was an open-label, single sequence study where subjects (n = 36) received pradigastat (100 mg once daily x 3 days thereafter 40 mg once daily) and rosuvastatin (10 mg once daily), alone and in combination. RESULTS: Pradigastat inhibited BCRP-mediated efflux activity in a dose-dependent fashion in a BCRP over-expressing human ovarian cancer cell line with an IC(50) value of 5 muM. Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17beta glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 +/- 0.95 muM, 3.34 +/- 0.64 muM, and 0.973 +/- 0.11 muM, respectively. In the presence of steady state pradigastat concentrations, AUC(tau, ss) of rosuvastatin was unchanged and its Cmax,ss decreased by 14% (5.30 and 4.61 ng/mL when administered alone and coadministered with pradigastat, respectively). Pradigastat AUC(tau, ss) and C(max, ss) were unchanged when coadministered with rosuvastatin at steady state. Both rosuvastatin and pradigastat were well tolerated. CONCLUSION: These data indicate no clinically relevant pharmacokinetic interaction between pradigastat and rosuvastatin.
Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazo l-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor.[Pubmed:24152122]
Xenobiotica. 2014 May;44(5):465-71.
1. A novel diacylglyceride acyltransferase-1 (DGAT-1) inhibitor, 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl) oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid (KR-69232), was synthesized for a potential therapeutic use against several metabolic disorders, such as obesity, insulin resistance, and type II diabetes, characterized by excessive triglycerides (TGs) in the blood. 2. The half-lives against phase I metabolism were measured as 75.3 +/- 20.9 min and over 120 min in rat and human liver microsomes, respectively. In Caco-2 cell monolayers, extremely low permeability (<0.13 x 10(-)(6)cm/s) was seen in the absorptive direction, predicting limited intestinal absorption of KR-69232. This compound was highly bound to rat and human plasma proteins (>99.8%). 3. With the intravenous administration of KR-69232 in rats (1, 2, and 5 mg/kg), non-linear kinetics were observed at the highest dose, with significantly higher systemic clearance, higher volume of distribution, and lower dose-normalized AUC. Following oral administration, it exhibited low bioavailability (<10%) and was absorbed slowly (T(max), 3.8-5.2 h) over the dose range. We also confirmed that considerable KR-69232 remained in the intestine at T(max), demonstrating its limited absorption into the systemic circulation.
Pharmacological characterization of [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6 -yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol transferase (DGAT) 1 inhibitor.[Pubmed:25747985]
Biol Pharm Bull. 2015;38(2):263-9.
Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 is an enzyme that catalyzes the final step in triglyceride (TG) synthesis. This enzyme is considered to be a potential therapeutic target for obesity and diabetes. Here, results of an investigation of the pharmacological effects of JTT-553 [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6 -yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate, a novel DGAT1 inhibitor, are reported. To measure the inhibitory activity of JTT-553 against DGAT1, TG synthesis using [(14)C]-labeled oleoyl-CoA was evaluated. Similarly, the inhibitory activity of JTT-553 against DGAT2, an isozyme of DGAT1, and acyl-CoA cholesterol acyltransferase (ACAT) 1, which is highly homologous to DGAT1, were evaluated. JTT-553 selectively inhibited human DGAT1 and showed comparable inhibitory effects on the activity of human, rat, and mouse DGAT. In vivo, JTT-553 suppressed plasma TG and chylomicron TG levels after olive oil loading in Sprague-Dawley (SD) rats. JTT-553 also inhibited TG synthesis in epididymal fat after [(14)C] oleic acid injection in C57BL/6J mice. Food intake was evaluated in SD rats fed 3.1%, 13%, or 35% (w/w) fat diets. In rats fed the 35% fat diet, JTT-553 reduced food intake. This reduction of food intake was observed 2 h after feeding, lasted for 24 h, and correlated with dietary fat content. Furthermore, JTT-553 reduced daily food intake and body weight gain in diet-induced obese rats after 4-week repeated administration. JTT-553 exerted multiple effects on intestinal fat absorption, adipose fat synthesis, and food intake, and consequently induced body weight reduction. Therefore, JTT-553 is expected to be an effective novel therapeutic agent for the treatment of obesity.